Applied Therapeutics, Inc. (NASDAQ:APLT) Insider Riccardo Perfetti Sells 465 Shares


Share on StockTwits

Applied Therapeutics, Inc. (NASDAQ:APLT) insider Riccardo Perfetti sold 465 shares of the business’s stock in a transaction that occurred on Tuesday, December 29th. The shares were sold at an average price of $21.95, for a total transaction of $10,206.75. Following the completion of the transaction, the insider now directly owns 465 shares of the company’s stock, valued at approximately $10,206.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Riccardo Perfetti also recently made the following trade(s):

  • On Wednesday, December 9th, Riccardo Perfetti sold 465 shares of Applied Therapeutics stock. The stock was sold at an average price of $20.46, for a total transaction of $9,513.90.
  • On Monday, December 7th, Riccardo Perfetti sold 465 shares of Applied Therapeutics stock. The shares were sold at an average price of $20.49, for a total value of $9,527.85.
  • On Monday, November 23rd, Riccardo Perfetti sold 465 shares of Applied Therapeutics stock. The stock was sold at an average price of $20.59, for a total value of $9,574.35.
  • On Friday, November 20th, Riccardo Perfetti sold 1,660 shares of Applied Therapeutics stock. The shares were sold at an average price of $19.07, for a total value of $31,656.20.
  • On Tuesday, November 10th, Riccardo Perfetti sold 200 shares of Applied Therapeutics stock. The shares were sold at an average price of $17.59, for a total value of $3,518.00.
  • On Tuesday, October 27th, Riccardo Perfetti sold 465 shares of Applied Therapeutics stock. The stock was sold at an average price of $21.20, for a total value of $9,858.00.
  • On Thursday, October 29th, Riccardo Perfetti sold 465 shares of Applied Therapeutics stock. The shares were sold at an average price of $17.27, for a total value of $8,030.55.

Shares of NASDAQ APLT opened at $22.01 on Friday. The stock has a fifty day moving average price of $21.22 and a 200 day moving average price of $24.93. Applied Therapeutics, Inc. has a 12-month low of $13.58 and a 12-month high of $57.39.

Applied Therapeutics (NASDAQ:APLT) last issued its earnings results on Tuesday, November 17th. The company reported ($1.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.02) by ($0.31). On average, analysts forecast that Applied Therapeutics, Inc. will post -4.51 earnings per share for the current year.

Several research analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Applied Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 13th. Truist began coverage on shares of Applied Therapeutics in a report on Thursday, October 8th. They issued a “buy” rating and a $85.00 price target on the stock. Barclays dropped their price objective on Applied Therapeutics from $64.00 to $44.00 in a report on Tuesday, November 17th. BidaskClub lowered Applied Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. Finally, ValuEngine raised Applied Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, October 19th. Two research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $56.43.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in APLT. FMR LLC raised its stake in shares of Applied Therapeutics by 64.7% during the second quarter. FMR LLC now owns 1,956,181 shares of the company’s stock valued at $70,716,000 after purchasing an additional 768,765 shares during the period. Bamco Inc. NY lifted its holdings in Applied Therapeutics by 181.4% in the 2nd quarter. Bamco Inc. NY now owns 253,491 shares of the company’s stock worth $9,164,000 after buying an additional 163,400 shares in the last quarter. Driehaus Capital Management LLC grew its stake in shares of Applied Therapeutics by 27.5% during the second quarter. Driehaus Capital Management LLC now owns 754,261 shares of the company’s stock valued at $27,267,000 after acquiring an additional 162,780 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its position in shares of Applied Therapeutics by 42.6% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 503,500 shares of the company’s stock worth $10,453,000 after acquiring an additional 150,522 shares during the last quarter. Finally, Kore Private Wealth LLC purchased a new stake in shares of Applied Therapeutics during the second quarter worth about $4,518,000. Hedge funds and other institutional investors own 52.11% of the company’s stock.

About Applied Therapeutics

Applied Therapeutics, Inc, a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that is in phase I/II for the treatment of galactosemia; AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy; and AT-003 that is in phase I clinical trial for the treatment diabetic retinopathy.

See Also: How does a security become overbought?

Insider Buying and Selling by Quarter for Applied Therapeutics (NASDAQ:APLT)

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.